| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Milk, Human | 8 | 2024 | 12 | 1.590 |
Why?
|
| Primary Health Care | 10 | 2026 | 78 | 1.340 |
Why?
|
| Humans | 73 | 2026 | 6794 | 1.210 |
Why?
|
| Male | 51 | 2025 | 3671 | 1.200 |
Why?
|
| Veterans | 9 | 2026 | 70 | 1.160 |
Why?
|
| Female | 49 | 2026 | 4060 | 1.150 |
Why?
|
| Middle Aged | 43 | 2026 | 2108 | 1.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2023 | 279 | 1.050 |
Why?
|
| Infant Nutritional Physiological Phenomena | 3 | 2024 | 4 | 0.980 |
Why?
|
| Infant, Very Low Birth Weight | 3 | 2024 | 6 | 0.910 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2024 | 7 | 0.850 |
Why?
|
| Aged | 29 | 2026 | 1539 | 0.840 |
Why?
|
| Iodine | 4 | 2024 | 11 | 0.820 |
Why?
|
| Testosterone | 8 | 2013 | 50 | 0.800 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2024 | 26 | 0.780 |
Why?
|
| Adult | 26 | 2025 | 2113 | 0.770 |
Why?
|
| Atherosclerosis | 3 | 2013 | 39 | 0.700 |
Why?
|
| United States Department of Veterans Affairs | 10 | 2026 | 25 | 0.690 |
Why?
|
| United States | 24 | 2026 | 1019 | 0.670 |
Why?
|
| Hemophilia B | 1 | 2020 | 1 | 0.670 |
Why?
|
| Factor IX | 1 | 2020 | 1 | 0.670 |
Why?
|
| Heart Failure | 4 | 2023 | 49 | 0.630 |
Why?
|
| Quality Improvement | 6 | 2021 | 31 | 0.600 |
Why?
|
| Aging | 3 | 2013 | 105 | 0.500 |
Why?
|
| Prediabetic State | 2 | 2014 | 28 | 0.500 |
Why?
|
| Androgens | 2 | 2013 | 24 | 0.470 |
Why?
|
| Adolescent | 13 | 2023 | 869 | 0.450 |
Why?
|
| Cholesterol | 2 | 2013 | 37 | 0.450 |
Why?
|
| Parenteral Nutrition | 3 | 2024 | 8 | 0.450 |
Why?
|
| Smoking Cessation | 3 | 2023 | 25 | 0.440 |
Why?
|
| Enterocolitis, Necrotizing | 3 | 2021 | 7 | 0.420 |
Why?
|
| Hypothyroidism | 2 | 2025 | 48 | 0.410 |
Why?
|
| Contrast Media | 2 | 2024 | 18 | 0.410 |
Why?
|
| Depression | 3 | 2025 | 128 | 0.410 |
Why?
|
| Hyperlipidemias | 2 | 2013 | 22 | 0.400 |
Why?
|
| African Americans | 2 | 2014 | 264 | 0.400 |
Why?
|
| Hyperthyroidism | 2 | 2023 | 18 | 0.390 |
Why?
|
| Synbiotics | 2 | 2023 | 3 | 0.390 |
Why?
|
| Insurance, Health | 1 | 2013 | 26 | 0.390 |
Why?
|
| Microbiota | 2 | 2023 | 8 | 0.390 |
Why?
|
| Anticholesteremic Agents | 1 | 2013 | 21 | 0.390 |
Why?
|
| Telemedicine | 3 | 2025 | 43 | 0.380 |
Why?
|
| Infant, Newborn | 6 | 2024 | 199 | 0.370 |
Why?
|
| Health Promotion | 3 | 2026 | 89 | 0.370 |
Why?
|
| Quality of Health Care | 4 | 2025 | 27 | 0.360 |
Why?
|
| Truth Disclosure | 1 | 2011 | 10 | 0.350 |
Why?
|
| Stereotyping | 1 | 2011 | 11 | 0.350 |
Why?
|
| Health Care Surveys | 2 | 2020 | 28 | 0.350 |
Why?
|
| Animals | 10 | 2024 | 1875 | 0.350 |
Why?
|
| Social Support | 1 | 2011 | 67 | 0.340 |
Why?
|
| Ischemic Attack, Transient | 2 | 2021 | 2 | 0.340 |
Why?
|
| Self-Management | 2 | 2021 | 3 | 0.340 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2011 | 72 | 0.330 |
Why?
|
| Mental Health Services | 2 | 2025 | 15 | 0.330 |
Why?
|
| Retrospective Studies | 11 | 2023 | 681 | 0.330 |
Why?
|
| Electronic Health Records | 2 | 2024 | 34 | 0.330 |
Why?
|
| Nicotine | 4 | 2024 | 144 | 0.330 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 506 | 0.320 |
Why?
|
| HIV Infections | 3 | 2011 | 432 | 0.320 |
Why?
|
| Lipids | 3 | 2006 | 35 | 0.310 |
Why?
|
| Young Adult | 6 | 2018 | 567 | 0.310 |
Why?
|
| Oligosaccharides | 3 | 2024 | 4 | 0.300 |
Why?
|
| Hormone Replacement Therapy | 3 | 2025 | 17 | 0.300 |
Why?
|
| Peripheral Arterial Disease | 2 | 2019 | 4 | 0.300 |
Why?
|
| Lower Extremity | 2 | 2019 | 7 | 0.300 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2019 | 17 | 0.290 |
Why?
|
| Cushing Syndrome | 3 | 2018 | 23 | 0.280 |
Why?
|
| Risk Reduction Behavior | 2 | 2026 | 17 | 0.280 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 497 | 0.280 |
Why?
|
| Quality of Life | 5 | 2023 | 184 | 0.270 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 258 | 0.270 |
Why?
|
| Double-Blind Method | 7 | 2023 | 101 | 0.270 |
Why?
|
| Parkinson Disease | 2 | 2019 | 6 | 0.270 |
Why?
|
| Medication Adherence | 2 | 2021 | 64 | 0.270 |
Why?
|
| Infant, Premature | 2 | 2024 | 23 | 0.250 |
Why?
|
| Echocardiography | 2 | 2024 | 15 | 0.250 |
Why?
|
| Patient-Centered Care | 2 | 2024 | 14 | 0.240 |
Why?
|
| Hypertension | 2 | 2021 | 147 | 0.240 |
Why?
|
| Disease Management | 3 | 2019 | 33 | 0.240 |
Why?
|
| Hospitals, Veterans | 4 | 2020 | 9 | 0.240 |
Why?
|
| Weight Gain | 2 | 2024 | 28 | 0.240 |
Why?
|
| Vitamin K | 2 | 2016 | 3 | 0.240 |
Why?
|
| Veterans Health | 3 | 2023 | 9 | 0.240 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2018 | 15 | 0.240 |
Why?
|
| Blood Viscosity | 3 | 2021 | 6 | 0.230 |
Why?
|
| Dietary Fats | 2 | 2024 | 19 | 0.230 |
Why?
|
| Triiodothyronine, Reverse | 1 | 2025 | 4 | 0.230 |
Why?
|
| Patient Participation | 1 | 2026 | 32 | 0.230 |
Why?
|
| Triiodothyronine | 1 | 2025 | 54 | 0.220 |
Why?
|
| Risk Factors | 6 | 2023 | 767 | 0.210 |
Why?
|
| Heart | 1 | 2024 | 25 | 0.210 |
Why?
|
| Glycated Hemoglobin A | 5 | 2019 | 65 | 0.210 |
Why?
|
| Niacinamide | 1 | 2024 | 5 | 0.210 |
Why?
|
| Pyridinium Compounds | 1 | 2024 | 6 | 0.210 |
Why?
|
| Electrocardiography | 1 | 2024 | 36 | 0.210 |
Why?
|
| Burnout, Professional | 1 | 2024 | 12 | 0.210 |
Why?
|
| Bifidobacterium | 1 | 2024 | 1 | 0.210 |
Why?
|
| Mice | 7 | 2024 | 746 | 0.210 |
Why?
|
| Treatment Adherence and Compliance | 2 | 2020 | 3 | 0.210 |
Why?
|
| Atrial Flutter | 1 | 2023 | 1 | 0.200 |
Why?
|
| Cardiovascular Diseases | 1 | 2026 | 172 | 0.200 |
Why?
|
| Tobacco Use Disorder | 1 | 2023 | 10 | 0.200 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 16 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2018 | 155 | 0.200 |
Why?
|
| Stroke | 2 | 2021 | 46 | 0.200 |
Why?
|
| Thyroid Diseases | 1 | 2023 | 25 | 0.190 |
Why?
|
| Injections, Subcutaneous | 2 | 2020 | 14 | 0.190 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2002 | 2 | 0.190 |
Why?
|
| Sampling Studies | 1 | 2002 | 13 | 0.190 |
Why?
|
| Microcirculation | 2 | 2019 | 14 | 0.190 |
Why?
|
| Muscle, Skeletal | 5 | 2006 | 75 | 0.180 |
Why?
|
| Fatty Liver | 2 | 2024 | 59 | 0.180 |
Why?
|
| Drug Design | 2 | 2020 | 7 | 0.180 |
Why?
|
| Oxidative Stress | 2 | 2024 | 102 | 0.180 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 5 | 0.180 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 280 | 0.180 |
Why?
|
| Health Personnel | 2 | 2019 | 49 | 0.180 |
Why?
|
| Prospective Studies | 6 | 2024 | 331 | 0.180 |
Why?
|
| Hypoglycemic Agents | 3 | 2023 | 165 | 0.180 |
Why?
|
| Stroke Volume | 2 | 2024 | 20 | 0.170 |
Why?
|
| Mentoring | 1 | 2021 | 12 | 0.170 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2020 | 1 | 0.170 |
Why?
|
| Partial Thromboplastin Time | 1 | 2020 | 3 | 0.170 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 5 | 0.170 |
Why?
|
| Models, Molecular | 1 | 2020 | 6 | 0.170 |
Why?
|
| Dogs | 1 | 2020 | 18 | 0.170 |
Why?
|
| Biological Availability | 1 | 2020 | 8 | 0.170 |
Why?
|
| Urinary Incontinence | 1 | 2020 | 7 | 0.170 |
Why?
|
| Treatment Outcome | 7 | 2019 | 500 | 0.170 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 56 | 0.170 |
Why?
|
| Mass Screening | 3 | 2014 | 116 | 0.160 |
Why?
|
| Hospitals, Community | 1 | 2020 | 4 | 0.160 |
Why?
|
| Blood Pressure | 1 | 2021 | 112 | 0.160 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 31 | 0.160 |
Why?
|
| Birth Weight | 3 | 2018 | 33 | 0.160 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 231 | 0.160 |
Why?
|
| Hydroxychloroquine | 1 | 2019 | 7 | 0.160 |
Why?
|
| Sulfonylurea Compounds | 1 | 2019 | 17 | 0.150 |
Why?
|
| Blood Coagulation Factors | 2 | 2016 | 2 | 0.150 |
Why?
|
| Metformin | 1 | 2019 | 35 | 0.150 |
Why?
|
| Respiratory Protective Devices | 1 | 2019 | 1 | 0.150 |
Why?
|
| Thyrotropin | 3 | 2023 | 51 | 0.150 |
Why?
|
| Occupational Health | 1 | 2019 | 7 | 0.150 |
Why?
|
| Equipment Design | 1 | 2019 | 20 | 0.150 |
Why?
|
| Workplace | 1 | 2019 | 10 | 0.140 |
Why?
|
| Diabetic Angiopathies | 1 | 2018 | 10 | 0.140 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2018 | 3 | 0.140 |
Why?
|
| Aspirin | 1 | 2018 | 11 | 0.140 |
Why?
|
| California | 3 | 2011 | 230 | 0.140 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 19 | 0.140 |
Why?
|
| Breast Feeding | 1 | 2018 | 14 | 0.140 |
Why?
|
| Internet | 1 | 2018 | 25 | 0.140 |
Why?
|
| Bridged Bicyclo Compounds | 1 | 2018 | 4 | 0.140 |
Why?
|
| Benzamides | 1 | 2018 | 11 | 0.140 |
Why?
|
| Dexamethasone | 1 | 2018 | 30 | 0.140 |
Why?
|
| Lanthanum | 1 | 2017 | 7 | 0.130 |
Why?
|
| Bone Diseases | 1 | 2017 | 7 | 0.130 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 13 | 0.130 |
Why?
|
| Infant Formula | 2 | 2018 | 2 | 0.130 |
Why?
|
| Infant, Extremely Premature | 2 | 2018 | 3 | 0.130 |
Why?
|
| Enteral Nutrition | 2 | 2018 | 13 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 8 | 0.130 |
Why?
|
| Depressive Disorder | 1 | 2016 | 28 | 0.130 |
Why?
|
| Dietary Proteins | 1 | 2017 | 53 | 0.130 |
Why?
|
| Diabetic Retinopathy | 1 | 2017 | 52 | 0.120 |
Why?
|
| Gene Transfer Techniques | 1 | 2016 | 7 | 0.120 |
Why?
|
| Adenoviridae | 1 | 2016 | 8 | 0.120 |
Why?
|
| Adenylyl Cyclases | 1 | 2016 | 2 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2016 | 13 | 0.120 |
Why?
|
| Plasma | 1 | 2016 | 6 | 0.120 |
Why?
|
| Health Services Accessibility | 2 | 2009 | 145 | 0.120 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 21 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2016 | 23 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2016 | 30 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2015 | 13 | 0.120 |
Why?
|
| Infant | 3 | 2023 | 187 | 0.120 |
Why?
|
| Hydrocortisone | 2 | 2018 | 33 | 0.120 |
Why?
|
| Receptors, Androgen | 2 | 2006 | 20 | 0.120 |
Why?
|
| Drug Resistance | 1 | 2015 | 16 | 0.120 |
Why?
|
| Hyperglycemia | 1 | 2015 | 27 | 0.110 |
Why?
|
| Drug Monitoring | 1 | 2015 | 16 | 0.110 |
Why?
|
| Time Factors | 4 | 2019 | 321 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2023 | 285 | 0.110 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2015 | 3 | 0.110 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 39 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2013 | 66 | 0.110 |
Why?
|
| Asthma | 1 | 2015 | 31 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2024 | 140 | 0.110 |
Why?
|
| Insulin | 1 | 2015 | 146 | 0.110 |
Why?
|
| Triglycerides | 2 | 2021 | 58 | 0.110 |
Why?
|
| Waist Circumference | 1 | 2014 | 8 | 0.100 |
Why?
|
| Community Health Services | 1 | 2014 | 35 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 84 | 0.100 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 13 | 0.100 |
Why?
|
| Body Composition | 2 | 2011 | 47 | 0.100 |
Why?
|
| Morphine Dependence | 1 | 2013 | 9 | 0.100 |
Why?
|
| Medicaid | 1 | 2013 | 19 | 0.100 |
Why?
|
| Gestational Age | 3 | 2021 | 58 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2013 | 38 | 0.100 |
Why?
|
| Eating | 1 | 2013 | 31 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2013 | 30 | 0.100 |
Why?
|
| Morphine | 1 | 2013 | 47 | 0.100 |
Why?
|
| Brain | 1 | 2013 | 94 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2013 | 58 | 0.100 |
Why?
|
| Dysbiosis | 2 | 2023 | 10 | 0.100 |
Why?
|
| Chronic Disease | 2 | 2020 | 167 | 0.090 |
Why?
|
| Vitamin D | 1 | 2012 | 45 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2013 | 145 | 0.090 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2012 | 27 | 0.090 |
Why?
|
| Research Design | 2 | 2025 | 41 | 0.090 |
Why?
|
| Needs Assessment | 2 | 2009 | 16 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2012 | 52 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2017 | 457 | 0.090 |
Why?
|
| Bisexuality | 1 | 2011 | 20 | 0.090 |
Why?
|
| Sexual Partners | 1 | 2011 | 49 | 0.090 |
Why?
|
| Risk-Taking | 1 | 2011 | 77 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2008 | 84 | 0.080 |
Why?
|
| Patient Outcome Assessment | 2 | 2021 | 5 | 0.080 |
Why?
|
| Secondary Prevention | 2 | 2021 | 16 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2011 | 60 | 0.080 |
Why?
|
| Anti-HIV Agents | 1 | 2011 | 102 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 82 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 268 | 0.080 |
Why?
|
| Cholesterol, LDL | 2 | 2007 | 35 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2006 | 82 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2007 | 64 | 0.080 |
Why?
|
| United States Indian Health Service | 1 | 2009 | 1 | 0.080 |
Why?
|
| Health Services | 1 | 2009 | 12 | 0.080 |
Why?
|
| Health Services Research | 1 | 2009 | 27 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 104 | 0.070 |
Why?
|
| Blood Flow Velocity | 2 | 2019 | 11 | 0.070 |
Why?
|
| Regional Blood Flow | 2 | 2019 | 17 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2019 | 27 | 0.070 |
Why?
|
| Patient Care Management | 1 | 2008 | 4 | 0.070 |
Why?
|
| Family Relations | 1 | 2008 | 7 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2008 | 19 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2008 | 61 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2008 | 35 | 0.070 |
Why?
|
| Caregivers | 1 | 2008 | 29 | 0.070 |
Why?
|
| Alzheimer Disease | 1 | 2008 | 30 | 0.070 |
Why?
|
| Dementia | 1 | 2007 | 14 | 0.070 |
Why?
|
| Pituitary Gland | 1 | 2007 | 40 | 0.070 |
Why?
|
| Endarterectomy, Carotid | 1 | 2007 | 5 | 0.060 |
Why?
|
| Muscle Contraction | 2 | 2004 | 13 | 0.060 |
Why?
|
| Coronary Artery Bypass | 1 | 2007 | 15 | 0.060 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2007 | 15 | 0.060 |
Why?
|
| Apolipoproteins B | 1 | 2006 | 6 | 0.060 |
Why?
|
| Demography | 1 | 2006 | 26 | 0.060 |
Why?
|
| Colonoscopy | 1 | 2006 | 10 | 0.060 |
Why?
|
| Cholesterol, HDL | 1 | 2006 | 23 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2016 | 15 | 0.060 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2006 | 10 | 0.060 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2006 | 4 | 0.060 |
Why?
|
| Nutrition Surveys | 1 | 2006 | 67 | 0.060 |
Why?
|
| Intrauterine Devices | 1 | 2006 | 1 | 0.060 |
Why?
|
| Contraceptive Agents | 1 | 2006 | 2 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 23 | 0.060 |
Why?
|
| Body Weight | 3 | 2013 | 90 | 0.060 |
Why?
|
| International Normalized Ratio | 2 | 2016 | 3 | 0.060 |
Why?
|
| Women's Health | 1 | 2026 | 24 | 0.060 |
Why?
|
| Postmenopause | 1 | 2005 | 10 | 0.060 |
Why?
|
| Databases, Factual | 3 | 2016 | 81 | 0.060 |
Why?
|
| Chromatography, Liquid | 1 | 2025 | 6 | 0.060 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2025 | 8 | 0.060 |
Why?
|
| Thyroxine | 1 | 2025 | 33 | 0.060 |
Why?
|
| HIV Wasting Syndrome | 1 | 2004 | 2 | 0.060 |
Why?
|
| Smoking | 2 | 2022 | 86 | 0.060 |
Why?
|
| Androstenedione | 1 | 2004 | 4 | 0.060 |
Why?
|
| Hypogonadism | 1 | 2004 | 10 | 0.060 |
Why?
|
| Weight Loss | 1 | 2004 | 35 | 0.050 |
Why?
|
| Thyroid Function Tests | 1 | 2024 | 17 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 50 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 57 | 0.050 |
Why?
|
| High Fructose Corn Syrup | 1 | 2024 | 5 | 0.050 |
Why?
|
| Therapy, Computer-Assisted | 2 | 2018 | 4 | 0.050 |
Why?
|
| Bifidobacterium longum subspecies infantis | 1 | 2024 | 1 | 0.050 |
Why?
|
| Exercise | 2 | 2021 | 55 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2024 | 71 | 0.050 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2024 | 35 | 0.050 |
Why?
|
| Veillonella | 1 | 2023 | 1 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 7 | 0.050 |
Why?
|
| Tobacco Use | 1 | 2023 | 7 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2023 | 8 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2015 | 258 | 0.050 |
Why?
|
| Muscle Fatigue | 1 | 2003 | 1 | 0.050 |
Why?
|
| Leg | 1 | 2003 | 5 | 0.050 |
Why?
|
| Liver | 1 | 2024 | 157 | 0.050 |
Why?
|
| Prebiotics | 1 | 2023 | 3 | 0.050 |
Why?
|
| Public Health | 1 | 2023 | 40 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2002 | 8 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2002 | 39 | 0.050 |
Why?
|
| Outpatients | 1 | 2002 | 10 | 0.050 |
Why?
|
| Hospitals, Urban | 1 | 2002 | 10 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 42 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2015 | 188 | 0.050 |
Why?
|
| Interviews as Topic | 2 | 2018 | 77 | 0.050 |
Why?
|
| Smokers | 1 | 2022 | 8 | 0.050 |
Why?
|
| Logistic Models | 2 | 2016 | 165 | 0.050 |
Why?
|
| Lipoproteins, VLDL | 1 | 2021 | 2 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2021 | 7 | 0.050 |
Why?
|
| Child | 2 | 2015 | 524 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 73 | 0.040 |
Why?
|
| Cattle | 1 | 2021 | 13 | 0.040 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2021 | 2 | 0.040 |
Why?
|
| Nurse Practitioners | 1 | 2021 | 4 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 13 | 0.040 |
Why?
|
| Community Health Workers | 1 | 2021 | 13 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 36 | 0.040 |
Why?
|
| Physician Assistants | 1 | 2021 | 12 | 0.040 |
Why?
|
| Safety-net Providers | 1 | 2021 | 24 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 35 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2020 | 18 | 0.040 |
Why?
|
| Medical Records | 2 | 2015 | 23 | 0.040 |
Why?
|
| Physicians | 1 | 2021 | 49 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 64 | 0.040 |
Why?
|
| Diet | 1 | 2021 | 111 | 0.040 |
Why?
|
| Antimalarials | 1 | 2019 | 4 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 20 | 0.040 |
Why?
|
| Hospitalization | 1 | 2020 | 128 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 89 | 0.040 |
Why?
|
| New York City | 1 | 2019 | 14 | 0.040 |
Why?
|
| Nurses | 1 | 2019 | 8 | 0.040 |
Why?
|
| Inhalation Exposure | 1 | 2019 | 9 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2019 | 12 | 0.040 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2018 | 5 | 0.040 |
Why?
|
| Milk | 1 | 2018 | 1 | 0.040 |
Why?
|
| Health Information Exchange | 1 | 2018 | 2 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2018 | 5 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2008 | 28 | 0.030 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2018 | 7 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2018 | 16 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 28 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2018 | 59 | 0.030 |
Why?
|
| Phosphorus | 1 | 2017 | 43 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2008 | 197 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2018 | 246 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 98 | 0.030 |
Why?
|
| Exercise Test | 1 | 2016 | 9 | 0.030 |
Why?
|
| Patient Admission | 1 | 2016 | 10 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 147 | 0.030 |
Why?
|
| Decision Trees | 1 | 2016 | 6 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2016 | 3 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 155 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2016 | 16 | 0.030 |
Why?
|
| Cardiac Catheterization | 1 | 2016 | 43 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2015 | 14 | 0.030 |
Why?
|
| Urban Health Services | 1 | 2015 | 17 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2015 | 25 | 0.030 |
Why?
|
| Age Factors | 1 | 2015 | 193 | 0.030 |
Why?
|
| Los Angeles | 1 | 2015 | 321 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2013 | 5 | 0.030 |
Why?
|
| Drug Implants | 1 | 2013 | 16 | 0.030 |
Why?
|
| Texas | 1 | 2013 | 9 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2013 | 16 | 0.030 |
Why?
|
| Narcotic Antagonists | 1 | 2013 | 29 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 41 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2013 | 73 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2012 | 4 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2012 | 5 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2012 | 40 | 0.020 |
Why?
|
| Motivation | 1 | 2012 | 42 | 0.020 |
Why?
|
| Austria | 1 | 2012 | 2 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2012 | 4 | 0.020 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2012 | 5 | 0.020 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2012 | 3 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2012 | 82 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2012 | 44 | 0.020 |
Why?
|
| Abdominal Fat | 1 | 2011 | 6 | 0.020 |
Why?
|
| Adiposity | 1 | 2011 | 20 | 0.020 |
Why?
|
| Energy Intake | 1 | 2011 | 30 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 169 | 0.020 |
Why?
|
| Adrenocortical Hyperfunction | 1 | 2010 | 2 | 0.020 |
Why?
|
| Saliva | 1 | 2010 | 7 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 259 | 0.020 |
Why?
|
| Home Nursing | 1 | 2008 | 1 | 0.020 |
Why?
|
| Community Networks | 1 | 2008 | 7 | 0.020 |
Why?
|
| Software | 1 | 2008 | 18 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 28 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 19 | 0.020 |
Why?
|
| Health Status | 1 | 2008 | 83 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2007 | 18 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2008 | 60 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 153 | 0.020 |
Why?
|
| Occult Blood | 1 | 2006 | 4 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 2006 | 2 | 0.020 |
Why?
|
| Enema | 1 | 2006 | 2 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2006 | 17 | 0.020 |
Why?
|
| Myogenin | 1 | 2006 | 1 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2006 | 6 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2006 | 5 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2006 | 21 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2006 | 11 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2006 | 5 | 0.020 |
Why?
|
| Cell Count | 1 | 2006 | 18 | 0.020 |
Why?
|
| Cell Division | 1 | 2006 | 40 | 0.020 |
Why?
|
| Biopsy | 1 | 2006 | 36 | 0.020 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2006 | 1 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2006 | 10 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 118 | 0.020 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2005 | 2 | 0.010 |
Why?
|
| Gels | 1 | 2005 | 5 | 0.010 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2005 | 5 | 0.010 |
Why?
|
| Hematocrit | 1 | 2005 | 12 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 2005 | 19 | 0.010 |
Why?
|
| Placebos | 1 | 2005 | 10 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2005 | 15 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2005 | 20 | 0.010 |
Why?
|
| Prostate | 1 | 2005 | 15 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 2005 | 21 | 0.010 |
Why?
|
| Menstruation | 1 | 2004 | 3 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2004 | 12 | 0.010 |
Why?
|
| Ligands | 1 | 2004 | 17 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 69 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 56 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2004 | 48 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 101 | 0.010 |
Why?
|
| Registries | 1 | 2004 | 63 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 2003 | 8 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2003 | 14 | 0.010 |
Why?
|